<?xml version="1.0" encoding="UTF-8"?>
<p id="par0010">The current treatments used for COVID-19 majorly include Convalescent plasma therapy which is based on the concept of passive immunity. Chenguang et al. (2020), carried out an experiment to find out if convalescent plasma transfusion can be beneficial in the cure of vitally infected patients of SARS-CoV-2 and it was found that the primary study showed positive outcome in the patientâ€™s medical status [
 <xref rid="bib0035" ref-type="bibr">7</xref>]. Protease inhibitor is commonly used for the management of HIV and this was used for the cure of COVID-19 in a preliminary study [
 <xref rid="bib0040" ref-type="bibr">8</xref>]. Nuceloside analogues including umifenovir, neuraminidase inhibitors, tenofovir disoproxil, remdesivir and lamivudine has been reported by Siti et al. (2020) for the antiviral treatments for human pathogenic CoVs [
 <xref rid="bib0045" ref-type="bibr">9</xref>]. Even though large numbers of these drugs are showing action for coronavirus in both in vitro along with in vivo, their side effects in terms of pharmacokinetic and pharmacodynamic properties are yet to be studied on animal and human trials. Moreover it will take quite a long time to give dependable and reliable treatment to patients. All of the drug options for COVID-19 are being tested from the previous pandemics treatment experience. However, each treatment options have its own advantages and limitations.
</p>
